CXL-1020
Based on 1 publication(s) in Google Scholar
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure.
For research use only. We do not sell to patients.
- CAS No.: 950834-06-7
- Formula: C7H9NO5S2
- Molecular Weight:251.28
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) CXL-1020
MoreAll Calcium Channel Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
L-type calcium channel |
In Vivo
CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction by isoproterenol)[1]
-
Dosage:100 μg/kg/min
-
Administration:For 30 min
-
Result:Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice.
-
Animal Model:Dogs (coronary microembolization-induced heart failure)[2] 3 and 10 mg/kg/min
-
Dosage:3 and 10 mg/kg/min
-
Administration:4-hour intravenous infusion
-
Result:Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 950834-06-7
-
Appearance Solid
-
Molecular Weight 251.28
-
Formula C7H9NO5S2
-
Color White to off-white
-
SMILES
CS(=O)(C1=C(S(=O)(NO)=O)C=CC=C1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
PLoS One
Nitroxyl protects H9C2 cells from H/R-induced damage and inhibits autophagy via PI3K/Akt/mTOR pathway. [Abstract]2025 Jan 29;20(1):e0314500. PMID: 39879163
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)